In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance .
A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.
In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.
A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.
Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.
The registry will provide data vital to improving understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.
Research led by investigators at Memorial Sloan Kettering Cancer Center has shown for the first time that organoids derived from human prostate cancer tumors can be grown in the laboratory, giving researchers an exciting new tool to test cancer drugs and personalize cancer treatment.
Ephraim Casper, MD, has been appointed Medical Director for the Memorial Sloan Kettering Regional Care Network, comprised of six outpatient suburban locations — three on Long Island; two in Westchester County, New York; and one in Basking Ridge, New Jersey.
Babies who are born with severe combined immunodeficiency (SCID) can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard J. O’Reilly, MD.
Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals.
Memorial Sloan Kettering Cancer Center (MSK) is partnering with DigitasLBi and Phase2 to help expand MSK’s digital reach.
Memorial Sloan Kettering Cancer Center and Quest Diagnostics announced a joint collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors. The goal is to use molecular laboratory testing to improve physicians’ ability to treat patients with breast, prostate, colon, lung, and a variety of other solid tumor cancers by giving them a better understanding of the genomic underpinnings of their patients’ illnesses.
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Memorial Sloan Kettering Cancer Center launched the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, an ambitious initiative to improve cancer care and research through genomic analysis.
New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.
Three winners of the first-ever Breakthrough Prizes— Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.
New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.
Memorial Sloan Kettering announced the appointment of Pereira & O’Dell in New York as its creative agency of record and Media Storm as its media agency of record.
The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells.
Memorial Sloan Kettering Cancer Center and Eureka Therapeutics recently entered into a licensing agreement with Novartis to develop a unique monoclonal antibody.
Memorial Sloan-Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.
Michael A. Foley, PhD, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University and Memorial Sloan-Kettering Cancer Center that is designed to expedite early-stage drug discovery into novel treatments for patients.
Memorial Sloan-Kettering Cancer Center has announced the appointment of surgical oncologist Richard Barakat to the new position of Deputy Physician-in-Chief for the Memorial Sloan-Kettering Regional Care Network and Alliance.
Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. and have partnered with Takeda Pharmaceutical Company, Ltd.
Memorial Sloan-Kettering Cancer Center is leading an innovative initiative to reduce cancer and cardiovascular health disparities in South Asian immigrant communities in the United States.
Memorial Sloan-Kettering Cancer Center today launched a transformative initiative to improve the quality of cancer care and the lives of cancer patients. Hartford HealthCare, a multi-hospital health care system in Connecticut, was selected as a pioneering member of the newly formed Memorial Sloan-Kettering Cancer Alliance.
For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.
Memorial Sloan-Kettering Cancer Center has announced the appointment of David R. Jones as Chief of the Thoracic Service in the Department of Surgery, and Charles M. Rudin as Chief of the Thoracic Oncology Service, Division of Solid Tumor Oncology, in the Department of Medicine.
A Memorial Sloan-Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
Memorial Sloan-Kettering Cancer Center today unveiled a new pressroom for journalists with enhanced features as well as the availability of an on-site broadcast studio.
A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor's pathology could be an important factor doctors use to guide cancer treatment decisions.
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to new research from Memorial Sloan-Kettering Cancer Center.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).
An analysis of endometrial cancers reveals genetic information that should improve diagnosis and guide treatments for women with an aggressive form of the disease.
Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create a unique monoclonal antibody that can effectively reach inside a cancer cell.
Memorial Sloan-Kettering Cancer Center has announced the appointment of Avice Meehan to Vice President of Communications and Chief Communications Officer.
Memorial Sloan-Kettering Cancer Center announces new appointments.
Charles L. Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program (HOPP), was awarded the Breakthrough Prize in Life Sciences today.
Memorial Sloan-Kettering Cancer Center researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.
IBM (NYSE: IBM), WellPoint, Inc. (NYSE: WLP), and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.
Memorial Sloan-Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research.
A new pancreatic cancer research center has been created at Memorial Sloan-Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.
Memorial Sloan-Kettering Cancer Center announced today that José Baselga has been named Physician-in-Chief of Memorial Hospital.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right